重组人尿激酶原静脉溶栓治疗负荷STEMI患者对冠脉血流及心肌灌注的影响

摘要/Abstract

摘要： 目的探讨重组人尿激酶原静脉溶栓治疗负荷STEMI患者对冠脉血流及心肌灌注的影响。方法选取2019年1月~2022年1月新疆生产建设兵团医院收治的120例高血栓负荷急性ST段抬高型心肌梗死（STEMI）患者,应用随机数表法分为观察组与对照组,每组60例。观察组患者给予重组人尿激酶原静脉溶栓治疗,对照组患者给予尿激酶治疗,对比两组患者的心功能指标、冠状动脉血流、心肌灌注以及不良心血管事件发生率。结果通过对比两组患者治疗前后心功能发现,两组患者治疗前左室收缩末期内径（LVESD）、左室舒张末期内径（LVEDD）、左室射血分数（LVEF）水平对比,差异无统计学意义（P>0.05）,两组患者治疗后LVESD、LVEDD、LVEF心功能相关指标均明显改善,差异有统计学意义（P<0.05）,治疗后两组间对比,差异无统计学意义（P>0.05）;两组患者治疗前0~1级、2级、3级冠状动脉血流情况对比,差异无统计学意义（P>0.05）,治疗后,观察组患者0~1级冠状动脉血流情况对比,差异无统计学意义（P>0.05）,观察组2级动脉血流人数低于对照组,3级动脉血流人数高于对照组,差异具有统计学意义（P<0.05）;两组患者治疗后,观察组ST段回落率、心肌染色分级（MBG）3级比例明显高于对照组,校正TIMI计帧数（CTFC）和无复流（NR）发生率明显低于对照组,差异有统计学意义（P<0.05）;两组患者不良心血管事件总发生率对比,差异无统计学意义（P>0.05）。结论重组人尿激酶原静脉溶栓可提高患者血管再通情况,改善冠脉血流及心肌灌注,效果确切,安全性好,值得临床应用。

关键词: 静脉溶栓, 重组人尿激酶原, STEMI, 冠脉血流, 心肌灌注

Abstract: Objective To investigate the effects of intravenous thrombolysis with recombinant human urokinase on coronary blood flow and myocardial perfusion in patients with ST segment elevation myocardial infarction. Methods From January 2019 to January 2022, 120 patients with high thrombotic load acute ST segment elevation myocardial infarction (STEMI) treated in Xinjiang production and Construction Corps Hospital were randomly divided into study group and control group, with 60 cases in each group. Patients in the study group were treated with recombinant human urokinase and patients in the control group were treated with urokinase. The cardiac function index, coronary blood flow, myocardial perfusion and the incidence of cardiovascular adverse events were compared between the two groups. Results There was no statistical significant difference in left ventricular end systolic diameter (LVESD), left ventricular end diastolic diameter (LVEDd) and left ventricular ejection fraction (LVEF) between the two groups before and after treatment (P>0.05). After treatment, LVESD, LVEDd and LVEF were significantly improved (P<0.05), and there was no statistical significant difference between the two groups (P>0.05); There was no statistical significant difference in grade 0-1(P>0.05), grade 2 and grade 3 coronary artery blood flow between the two groups before treatment (P<0.05), and there was no significant difference in grade 0-1 coronary artery blood flow between the observation group after treatment(P>0.05). The number of grade 2 coronary artery blood flow in the observation group was lower than that in the control group, and the number of grade 3 coronary artery blood flow in the observation group was higher than that in the control group (P<0.05); The rate of ST treatment decline and myocardial staining grade (MBG) 3 in the two groups were significantly higher than those in the control group (P<0.05), CTFC (corrected TIMI frame number) and NR (no reflow) incidence were significantly lower than those in the control group (P<0.05); There was no statistical significant difference in the total incidence of adverse cardiovascular events between the two groups (P>0.05). Conclusion Intravenous thrombolysis with recombinant human urokinase can improve vascular recanalization, coronary blood flow and myocardial perfusion. The effect is positive and the safety is good. It is worthy of clinical application.

Key words: intravenous thrombolysis, recombinant human prourokinase, STEMI, coronary blood flow, myocardial perfusion

中图分类号:

R714.525

郭雪峰. 重组人尿激酶原静脉溶栓治疗负荷STEMI患者对冠脉血流及心肌灌注的影响[J]. 中华养生保健, 2022, 40(17): 21-23.

GUO Xue-feng. Effects of Recombinant Human Prourokinase Intravenous Thrombolysis on Coronary Blood Flow in Patients with Stress STEMI and Myocardialperfusion[J]. ZHONGHUA YANGSHENG BAOJIAN, 2022, 40(17): 21-23.

参考文献

[1] 施巍. 美托洛尔对急性ST段抬高型心肌梗死患者自主神经失衡的影响[J].中国药业,2015,24(22):46-48.
[2] 张楠. 替罗非班在急性ST段抬高型心肌梗死行PCI术患者中应用的最佳时机叨.中国医药导报,2018,15(8):124-128.
[3] 张伯亨,张亚静,岳博成,等.尿激酶原联合血栓抽吸对高血栓负荷的sTEMI患者的疗效观察[J].医学研究杂志,2018,47(5):179-182.
[4] 洪涛. 冠状动脉TIMI血流分级[J].中国介入心脏病学杂志,2003, 11(3):154-154.
[5] 郝清卿,王立立,安少波,等.重组尿激酶原联合替罗非班在急性心肌梗死介入治疗中的作用[J].中国临床药理学杂志,2017,33(21):2098-2100.
[6] 张蕊. sT段抬高型急性心肌梗死患者溶栓治疗中常规剂量替罗非班联合半剂量瑞替普酶的应用效果分析[J].中国实用医药,2018, 13(12):99-101.
[7] 郑望,邓兵,沈琳,等.重组人尿激酶原联合替罗非班在高血栓负荷急性sT段抬高型心肌梗死患者急诊经皮冠状动脉介人治疗中的应用效果[J].实用心脑肺血管病杂志,2018,26(5):91-92.
[8] 隆海文,谢迎春,甘剑挺,等.老年ST段抬高型急性心肌梗死转运PcI应用替罗非班的临床观察[J].心脑血管病防治,2018,18(1):54-56.
[9] 刘志坚,冯冀,刘志辉,等.溶栓后PCI与pPcI治疗急性sT段抬高型心肌梗死的临床效果比较[J].基层医学论坛,2018,22(4):520-522.
[10] 耿宏旭. 急性ST段抬高型心肌梗死PCI术中冠状动脉内注射替罗非班对改善心肌灌注的临床研究[J].中国实用医刊,2018,45(9):68-70.
[11] 张靖,舒民,姚明言,等.血栓抽吸联合重组人尿激酶原预处理对高血栓负荷STEMI患者冠脉血流及心肌灌注的影响[J].天津医药,2020,48(6):539-542.
[12] 王海洋,刘琳,申文宇,等.冠状动脉内注射重组人尿激酶原对STEMI病人急诊PCI术后心肌血流灌注的影响[J].中西医结合心脑血管病杂志,2022,20(1):124-127.
[13] 赵广文,张燕,钱福东.PCI术中冠状动脉内注射重组人尿激酶原对STEMI患者高血栓负荷的影响[J].安徽医学,2020,41(10):1160-1163.
[14] Li X X, Liu S H, Zhuang S J,et al.Effects of intravenous thrombolysis with alteplase combined with edaravone on cerebral hemodynamics and T lymphocyte level in patients with acute cerebral infarction[J].Medicine,2020,99(50):e23414.
[15] Liu Y, Yang Y, Li Y, et al.Comparison of Efficacy and Safety of Recombinant Human Prourokinase and Alteplase in the Treatment of STEMI and Analysis of Influencing Factors of Efficacy[J].Evidence-based Complementary and Alternative Medicine,2021,2021(12):1-6.
[16] 韩梅,张驰,冯琚,等.重组人尿激酶原对老年性ST段抬高型心肌梗死患者近期心血管事件影响分析[J].中国心血管病研究,2018,16(5): 411-415.
[17] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2016, 8(38):675-687.
[18] 张春龙,彭绪东.重组人尿激酶原治疗急性ST段抬高型心肌梗死患者的临床研究[J].心肺血管病杂志,2017,36(6):436-439.